Evidence map›Paper›PMID 31485846›Full record

ReviewClinical rheumatology2019

Management of rheumatoid arthritis: 2019 updated consensus recommendations from the Hong Kong Society of Rheumatology.

Carmen Tze Kwan Ho, Chi Chiu Mok, Tommy Tsang Cheung, Kitty Yan Kwok, Ronald Man Lung Yip, Hong Kong Society of Rheumatology

Registry-linked trialAbstract readReviewConsensus Statement
PubMed Publisher
In one paragraph

Review in Clinical rheumatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04356404 (Risk of Hepatitis Flare in Patients With Previous Hepatitis B Virus Exposure Amongst Patients on Immunosuppressive and Biological Modifier Therapies Exposure), which is not on this map. Cited by 14 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04356404 terminatednot on this mapstarted 2020, after this paper: background citation

Risk of Hepatitis Flare in Patients With Previous Hepatitis B Virus Exposure Amongst Patients on Immunosuppressive and Biological Modifier Therapies Exposure

TypeobservationalSponsorChinese University of Hong KongRan2020 to 2022Enrolled68ConditionsOccult Hepatitis B, Biological Substance, Adverse Effect, Immunosuppression
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Mesenchymal Stem Cell-Based Therapy for Rheumatoid Arthritis.International journal of molecular sciences · 2021
    Review
  11. Article
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Carmen Tze Kwan HoQueen Mary Hospital, Pokfulam, Hong Kong.
Chi Chiu MokDepartment of Medicine, Tuen Mun Hospital, Tuen Mun, Hong Kong, China. ccmok2005@yahoo.com.ORCID http://orcid.org/0000-0003-3696-1228
Tommy Tsang CheungQueen Mary Hospital, Pokfulam, Hong Kong.
Kitty Yan KwokQueen Elizabeth Hospital, Yau Ma Tei, Hong Kong.
Ronald Man Lung YipHong Kong Society of Rheumatology, Tung Chau Street, Kowloon, Hong Kong.
Hong Kong Society of Rheumatology

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The expanding range of treatment options for rheumatoid arthritis (RA), from conventional synthetic disease-modifying antirheumatic drugs (DMARDs) to biological DMARDs (bDMARDs), biosimilar bDMARDs, and targeted synthetic DMARDs, has improved patient outcomes but increased the complexity of treatment decisions. These updated consensus recommendations from the Hong Kong Society of Rheumatology provide guidance on the management of RA, with a focus on how to integrate newly available DMARDs into clinical practice. The recommendations were developed based on evidence from the literature along with local expert opinion. Early diagnosis of RA and prompt initiation of effective therapy remain crucial and we suggest a treat-to-target approach to guide optimal sequencing of DMARDs in RA patients to achieve tight disease control. Newly available DMARDs are incorporated in the treatment algorithm, resulting in a greater range of second-line treatment options. In the event of treatment failure or intolerance, switching to another DMARD with a similar or different mode of action may be considered. Given the variety of available treatments and the heterogeneity of patients with RA, treatment decisions should be tailored to the individual patient taking into consideration prognostic factors, medical comorbidities, drug safety, cost of treatment, and patient preference.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidDisease ManagementHumansRheumatologyAntirheumatic AgentsConsensusDMARDsGuidelineManagementRheumatoid arthritis

Identifiers

PMID31485846

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.